185 related articles for article (PubMed ID: 27171671)
1. Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches.
David CA; Owen A; Liptrott NJ
Nanomedicine (Lond); 2016 Jun; 11(11):1447-64. PubMed ID: 27171671
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.
Dobrovolskaia MA
J Control Release; 2015 Dec; 220(Pt B):571-83. PubMed ID: 26348388
[TBL] [Abstract][Full Text] [Related]
3. Current understanding of interactions between nanoparticles and the immune system.
Dobrovolskaia MA; Shurin M; Shvedova AA
Toxicol Appl Pharmacol; 2016 May; 299():78-89. PubMed ID: 26739622
[TBL] [Abstract][Full Text] [Related]
4. Preclinical hazard evaluation strategy for nanomedicines.
Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
[TBL] [Abstract][Full Text] [Related]
5. Nanotoxicological classification system (NCS) - a guide for the risk-benefit assessment of nanoparticulate drug delivery systems.
Keck CM; Müller RH
Eur J Pharm Biopharm; 2013 Aug; 84(3):445-8. PubMed ID: 23333302
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Immune Mechanisms in the Pathologic Response to Particles, Fibers, and Nanomaterials.
Ma Q; Pollard KM; Brown JM; Italiani P; Moghimi SM
Front Immunol; 2021; 12():665810. PubMed ID: 33815427
[No Abstract] [Full Text] [Related]
7. Approach to using mechanism-based structure activity relationship (SAR) analysis to assess human health hazard potential of nanomaterials.
Lai DY
Food Chem Toxicol; 2015 Nov; 85():120-6. PubMed ID: 26111809
[TBL] [Abstract][Full Text] [Related]
8. The Nanopharmacology and Nanotoxicology of Nanomaterials: New Opportunities and Challenges.
Radomska A; Leszczyszyn J; Radomski MW
Adv Clin Exp Med; 2016; 25(1):151-62. PubMed ID: 26935510
[TBL] [Abstract][Full Text] [Related]
9. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications.
Fadeel B; Garcia-Bennett AE
Adv Drug Deliv Rev; 2010 Mar; 62(3):362-74. PubMed ID: 19900497
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Polymeric Nanoparticle Dispersions for Biomedical Applications: Size, Surface Charge and Stability.
Fornaguera C; Solans C
Pharm Nanotechnol; 2018; 6(3):147-164. PubMed ID: 29984674
[TBL] [Abstract][Full Text] [Related]
11. Characterization of nanoparticles for therapeutics.
Hall JB; Dobrovolskaia MA; Patri AK; McNeil SE
Nanomedicine (Lond); 2007 Dec; 2(6):789-803. PubMed ID: 18095846
[TBL] [Abstract][Full Text] [Related]
12. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies.
Gioria S; Caputo F; Urbán P; Maguire CM; Bremer-Hoffmann S; Prina-Mello A; Calzolai L; Mehn D
Nanomedicine (Lond); 2018 Mar; 13(5):539-554. PubMed ID: 29381129
[TBL] [Abstract][Full Text] [Related]
13. Toxicological Concerns of Engineered Nanosize Drug Delivery Systems.
Mukherjee B; Maji R; Roychowdhury S; Ghosh S
Am J Ther; 2016; 23(1):e139-50. PubMed ID: 24100254
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and efficacy of carbon nanotubes and graphene: the utility of carbon-based nanoparticles in nanomedicine.
Zhang Y; Petibone D; Xu Y; Mahmood M; Karmakar A; Casciano D; Ali S; Biris AS
Drug Metab Rev; 2014 May; 46(2):232-46. PubMed ID: 24506522
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters.
Gaumet M; Vargas A; Gurny R; Delie F
Eur J Pharm Biopharm; 2008 May; 69(1):1-9. PubMed ID: 17826969
[TBL] [Abstract][Full Text] [Related]
16. Toxicology of nanoparticles.
Elsaesser A; Howard CV
Adv Drug Deliv Rev; 2012 Feb; 64(2):129-37. PubMed ID: 21925220
[TBL] [Abstract][Full Text] [Related]
17. Safety of Nanoparticles in Medicine.
Wolfram J; Zhu M; Yang Y; Shen J; Gentile E; Paolino D; Fresta M; Nie G; Chen C; Shen H; Ferrari M; Zhao Y
Curr Drug Targets; 2015; 16(14):1671-81. PubMed ID: 26601723
[TBL] [Abstract][Full Text] [Related]
18. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology.
Oberdörster G
J Intern Med; 2010 Jan; 267(1):89-105. PubMed ID: 20059646
[TBL] [Abstract][Full Text] [Related]
19. Toxicological assessment of nanoparticle interactions with the pulmonary system.
Osman NM; Sexton DW; Saleem IY
Nanotoxicology; 2020 Feb; 14(1):21-58. PubMed ID: 31502904
[TBL] [Abstract][Full Text] [Related]
20. Integrated research into the nanoparticle-protein corona: a new focus for safe, sustainable and equitable development of nanomedicines.
Faunce TA; White J; Matthaei KI
Nanomedicine (Lond); 2008 Dec; 3(6):859-66. PubMed ID: 19025459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
